Free Trial

Jasper Therapeutics (JSPR) Stock Price, News & Analysis

Jasper Therapeutics logo
$21.18
-0.58 (-2.67%)
(As of 10/31/2024 ET)

About Jasper Therapeutics Stock (NASDAQ:JSPR)

Key Stats

Today's Range
$20.92
$22.05
50-Day Range
$14.72
$23.91
52-Week Range
$4.00
$31.01
Volume
170,949 shs
Average Volume
171,027 shs
Market Capitalization
$319.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.86
Consensus Rating
Buy

Company Overview

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Jasper Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
69th Percentile Overall Score

JSPR MarketRank™: 

Jasper Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 371st out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Jasper Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Jasper Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Jasper Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Jasper Therapeutics are expected to grow in the coming year, from ($4.16) to ($4.03) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Jasper Therapeutics is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Jasper Therapeutics is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Jasper Therapeutics has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Jasper Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    15.63% of the float of Jasper Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Jasper Therapeutics has a short interest ratio ("days to cover") of 7.3.
  • Change versus previous month

    Short interest in Jasper Therapeutics has recently increased by 21.48%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Jasper Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Jasper Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.63% of the float of Jasper Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Jasper Therapeutics has a short interest ratio ("days to cover") of 7.3.
  • Change versus previous month

    Short interest in Jasper Therapeutics has recently increased by 21.48%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Jasper Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Jasper Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    7 people have searched for JSPR on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Jasper Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,107.00 in company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of Jasper Therapeutics is held by insiders.

  • Percentage Held by Institutions

    79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Jasper Therapeutics' insider trading history.
Receive JSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JSPR Stock News Headlines

Oppenheimer Sticks to Their Buy Rating for Jasper Therapeutics (JSPR)
Jasper Therapeutics (NASDAQ:JSPR) Stock, Option Chain
Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
Jasper Therapeutics' (JSPR) Buy Rating Reiterated at HC Wainwright
See More Headlines

JSPR Stock Analysis - Frequently Asked Questions

Jasper Therapeutics' stock was trading at $7.89 at the beginning of 2024. Since then, JSPR stock has increased by 168.4% and is now trading at $21.18.
View the best growth stocks for 2024 here
.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) released its earnings results on Tuesday, August, 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.12.

Jasper Therapeutics shares reverse split on the morning of Thursday, January 4th 2024. The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Top institutional shareholders of Jasper Therapeutics include Fernwood Investment Management LLC (0.35%), AlphaCentric Advisors LLC (0.12%) and Wolff Wiese Magana LLC (0.02%). Insiders that own company stock include Velan Capital Investment Manag, Carlyle Group Inc, Holding Ltd Roche, Jeetinder Singh Mahal, Thomas G Wiggans and Anna Louise French.
View institutional ownership trends
.

Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Jasper Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

Last Earnings
8/13/2024
Today
10/31/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:JSPR
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$74.86
High Stock Price Target
$90.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+244.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-64,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.03 per share

Miscellaneous

Free Float
14,697,000
Market Cap
$328.68 million
Optionable
Optionable
Beta
2.21
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:JSPR) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners